Omar Husseini, MD
Cardiovascular Disease · Munster, INNPI 1467740894
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $40,200 of the $65,795 with a category attached, or 61.1%. Lantheus Medical Imaging, Inc. accounts for 64.2% of it on its own, with 35 other manufacturers making up the rest. Reporting peaked in 2022 at $16,039 and has fallen 76.8% since, to $3,721 in 2025. Among cardiovascular disease clinicians in IN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 425 payments — averaging $154.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lantheus Medical Imaging, Inc.$42K
- Edwards Lifesciences$14K
- Abbott$2K
- Boston Scientific$2K
- Novartis$1K
- Amgen$524
- plus $3K from 30 others
What the payments were for
- Consulting fees$8,50013%
- Speaking & faculty fees$40,20061%
- Travel & lodging$5,3158%
- Food & beverage$11,78018%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lantheus Medical Imaging, Inc. | 46 | $42,250 |
| Edwards Lifesciences | 49 | $14,108 |
| Abbott | 33 | $2,443 |
| Boston Scientific | 22 | $2,114 |
| Novartis | 91 | $1,276 |
| Amgen | 28 | $524 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 26 | $504 |
| Johnson & Johnson | 21 | $305 |
| Merck | 18 | $262 |
| Boehringer Ingelheim | 10 | $182 |
| Pfizer | 10 | $173 |
| AstraZeneca | 12 | $171 |
| Inspire Medical Systems, Inc. | 4 | $159 |
| Regeneron Healthcare Solutions, Inc. | 6 | $126 |
| Mylan Specialty L.p. | 1 | $125 |
| Biosense Webster, Inc. | 2 | $120 |
| Penumbra, Inc. | 1 | $117 |
| E.r. Squibb & Sons, L.L.C. | 7 | $106 |
| Sanofi-aventis U.S. LLC | 6 | $102 |
| Chiesi USA, Inc. | 6 | $95 |
| Atricure, Inc. | 3 | $75 |
| Scpharmaceuticals Inc. | 3 | $69 |
| Novo Nordisk | 2 | $50 |
| Actelion Pharmaceuticals US, Inc. | 2 | $39 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $38 |
| Cvrx, Inc. | 2 | $34 |
| Bolton Medical Inc | 1 | $32 |
| Lundbeck LLC | 2 | $29 |
| Bayer | 1 | $29 |
| Tactile Systems Technology Inc | 1 | $27 |
| Gilead | 2 | $26 |
| Astellas Pharma US Inc | 1 | $22 |
| Argon Medical Devices, Inc. | 1 | $20 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $17 |
| Esperion Therapeutics, Inc. | 1 | $14 |
| Vifor Pharma, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Definity$41,496
- PASCAL$9,031
- EVOQUE$3,383
- TRICLIP$1,020
- GENERAL - THERAPIES$864
- Watchman$459
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$250
- MitraClip$164
- WATCHMAN FLX$144
- WATCHMAN Access System$129
- Yupelri$125
- Indigo System$117
- Mitra Clip system$105
How this compares
$65,795 in reported general payments places this provider in the 90th percentile of 408 cardiovascular disease providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 267 | $301,789 |
| EntrestoSacubitril/Valsartan | 100 | $161,914 |
| XareltoRivaroxaban | 118 | $130,345 |
| Repatha SureclickEvolocumab | 86 | $72,313 |
| FarxigaDapagliflozin Propanediol | 45 | $56,214 |
| Praluent PenAlirocumab | 25 | $22,753 |
| BrilintaTicagrelor | 14 | $13,672 |
| Atorvastatin Calcium | 547 | $4,146 |
| Metoprolol Succinate | 363 | $4,121 |
| Dofetilide | 11 | $3,920 |
| Amiodarone Hcl | 21 | $3,102 |
| Ezetimibe | 74 | $2,867 |
| Bumetanide | 42 | $2,287 |
| Amlodipine Besylate | 349 | $1,820 |
| Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide | 18 | $1,733 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $173 | $301,789267 claims |
| NovartisEntresto | $1,276 | $161,914100 claims |
| Johnson & JohnsonXarelto | $305 | $130,345118 claims |
| AstraZenecaFarxiga, Brilinta | $171 | $69,88659 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 408 cardiovascular disease providers in Indiana.
Other cardiovascular disease in Munster
- Wail AsfourMunster$71K
- John MillerIndianapolis$354K
- David KovacichIndianapolis$327K
- Wai LeeElkhart$321K
- Anas SafadiHobart$295K
- Lawrence RinkBloomington$280K
- Vijay RaoIndianapolis$247K
- Steven SteinhublLafayette$247K
- Atul ChughIndianapolis$242K
- James TrippiIndianapolis$239K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.